£119.99

New Developments in Visual Attention Research (Psychology Research Progress)

Price data last checked 11 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£120 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 80 days · 80 data points (no recent data)

Historical
Generating forecast…
£119.99 £113.99 £116.39 £118.79 £121.19 £123.59 £125.99 28 June 2026 17 July 2026 06 August 2026 26 August 2026 15 September 2026

Price Distribution

Price distribution over 80 days • 1 price levels

Days at Price
80 days 0 20 40 60 80 £120 Days at Price

Price Analysis

Most common price: £120 (80 days, 100.0%)

Price range: £120 - £120

Price levels: 1 different prices over 80 days

Description

Poorly differentiated triple negative breast cancers (TNBCs) were first characterised in the literature in 2005 by the absence of receptors for estrogen (ER) and progesterone (PR) as well as the lack of tyrosine kinase human epidermal growth factor receptor 2 (HER-2). Clinically, TNBCs exhibit fairly aggressive local growth, rapid progression and account for a high rate of early metastases, most commonly to visceral organs and central nervous system. Chapter One describes how the last decade has contributed to our understanding of the function of exosomes in the progression of breast cancer. Furthermore, it will discuss the implications for using exosomes from body fluids as biomarkers in diagnosis and treatment strategies. Chapter Two discusses how the strong correlation between BRCA gene mutations and the high risk of TNBC proposes certain mediators between germline mutations and the risk for poorly differentiated breast cancers. Chapter Two presents increasing evidence of the role of tumour lymphocytic immune infiltrates in this subtype of breast cancer. High levels of tumour infiltrating lymphocytes (TILs), mainly in lymphocyte-predominant breast cancer (LPBC), have been associated with improved disease-free and overall survival rates in TNBC patients with and without any treatment.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
01 July 2017
Listed Since
20 July 2017

Barcode

No barcode data available

Similar Products You Might Like

Prognostic variables in node-negative and node-positive breast cancer
83% match

Prognostic variables in node-negative and node-positive breast cancer

Springer

£153.04 05 Aug 2026
Triple-Negative Breast Cancer: A Clinician’s Guide
81% match

Triple-Negative Breast Cancer: A Clinician’s Guide

Springer

£80.67 03 Aug 2026
Breast Cancer: Progress in Biology, Clinical Management and Prevention: Proceedings of the International Association for Breast Cancer Research ... March 1989: 58 (Developments in Oncology, 58)
79% match

Breast Cancer: Progress in Biology, Clinical Management and Prevention: Proceedings of the International Association for Breast Cancer Research ... March 1989: 58 (Developments in Oncology, 58)

Springer

£121.35 08 Aug 2026
Breast Cancer: Progress in Biology, Clinical Management and Prevention: Proceedings of the International Association for Breast Cancer Research ... March 1989: 58 (Developments in Oncology, 58)
79% match

Breast Cancer: Progress in Biology, Clinical Management and Prevention: Proceedings of the International Association for Breast Cancer Research ... March 1989: 58 (Developments in Oncology, 58)

Springer

£108.01 06 Aug 2026
Resistance to Targeted Therapies in Breast Cancer: 16 (Resistance to Targeted Anti-Cancer Therapeutics, 16)
79% match

Resistance to Targeted Therapies in Breast Cancer: 16 (Resistance to Targeted Anti-Cancer Therapeutics, 16)

Springer

£80.65 06 Aug 2026
Hormone Receptors in Breast Cancer: 147 (Cancer Treatment and Research, 147)
79% match

Hormone Receptors in Breast Cancer: 147 (Cancer Treatment and Research, 147)

Springer

£80.67 04 Aug 2026
Optimizing Breast Cancer Management: 173 (Cancer Treatment and Research, 173)
79% match

Optimizing Breast Cancer Management: 173 (Cancer Treatment and Research, 173)

Springer

£103.27 08 Aug 2026
Breast Cancer Risk Reduction and Early Detection
79% match

Breast Cancer Risk Reduction and Early Detection

Springer

£79.70 08 Aug 2026
Breast Cancer: Origins, Detection, and Treatment: Proceedings of the International Breast Cancer Research Conference London, United Kingdom ― March 24–28, 1985: 43 (Developments in Oncology, 43)
79% match

Breast Cancer: Origins, Detection, and Treatment: Proceedings of the International Breast Cancer Research Conference London, United Kingdom ― March 24–28, 1985: 43 (Developments in Oncology, 43)

Springer

£78.17 05 Aug 2026
Regulatory Mechanisms in Breast Cancer: Advances in Cellular and Molecular Biology of Breast Cancer: 53 (Cancer Treatment and Research, 53)
79% match

Regulatory Mechanisms in Breast Cancer: Advances in Cellular and Molecular Biology of Breast Cancer: 53 (Cancer Treatment and Research, 53)

Springer

£149.64 06 Aug 2026
Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer: 195 (Recent Results in Cancer Research, 195)
78% match

Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer: 195 (Recent Results in Cancer Research, 195)

Springer

£80.67 06 Aug 2026
Signaling Pathways in Breast Cancer: Molecular Mechanisms, Therapeutic Strategies, and Multidrug Resistance
78% match

Signaling Pathways in Breast Cancer: Molecular Mechanisms, Therapeutic Strategies, and Multidrug Resistance

Elsevier

£145.99 04 Aug 2026
Cell and Molecular Biology of Breast Cancer
78% match

Cell and Molecular Biology of Breast Cancer

Humana

£80.67 08 Aug 2026
Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment: Proceedings of the Fifth International Workshop on Breast Cancer ... in Experimental Medicine and Biology)
78% match

Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment: Proceedings of the Fifth International Workshop on Breast Cancer ... in Experimental Medicine and Biology)

Springer

£79.08 04 Aug 2026
Breast Cancer: Biological and Clinical Progress: Proceedings of the Conference of the International Association for Breast Cancer Research, St. ... 1991: 69 (Developments in Oncology, 69)
78% match

Breast Cancer: Biological and Clinical Progress: Proceedings of the Conference of the International Association for Breast Cancer Research, St. ... 1991: 69 (Developments in Oncology, 69)

Springer

£113.94 18 Aug 2026
Adjuvant Therapy of Breast Cancer V: 140 (Recent Results in Cancer Research, 140)
78% match

Adjuvant Therapy of Breast Cancer V: 140 (Recent Results in Cancer Research, 140)

Springer

£76.42 18 Aug 2026
Omics Approaches in Breast Cancer: Towards Next-Generation Diagnosis, Prognosis and Therapy
78% match

Omics Approaches in Breast Cancer: Towards Next-Generation Diagnosis, Prognosis and Therapy

Springer

£74.21 08 Aug 2026
Breast Cancer, An Issue of Hematology/Oncology Clinics of North America (Volume 27-4) (The Clinics: Internal Medicine, Volume 27-4)
78% match

Breast Cancer, An Issue of Hematology/Oncology Clinics of North America (Volume 27-4) (The Clinics: Internal Medicine, Volume 27-4)

Elsevier

£55.49 04 Aug 2026
Drugs for HER-2-positive Breast Cancer (Milestones in Drug Therapy)
78% match

Drugs for HER-2-positive Breast Cancer (Milestones in Drug Therapy)

Springer

£93.01 14 Sep 2026
Drugs for HER-2-positive Breast Cancer (Milestones in Drug Therapy)
78% match

Drugs for HER-2-positive Breast Cancer (Milestones in Drug Therapy)

Springer

£108.00 07 Aug 2026
A Practical Guide to Breast Cancer Treatment
77% match

A Practical Guide to Breast Cancer Treatment

Springer

£115.72 04 Aug 2026
Breast Cancer (MD Anderson Solid Tumor Oncology Series)
77% match

Breast Cancer (MD Anderson Solid Tumor Oncology Series)

Springer

£78.01 13 Aug 2026
Tumors of the Central Nervous system, Volume 3: Brain Tumors (Part 1)
77% match

Tumors of the Central Nervous system, Volume 3: Brain Tumors (Part 1)

Springer

£11.80 07 Aug 2026
Environment and Breast Cancer
77% match

Environment and Breast Cancer

Springer

£108.01 14 Aug 2026